{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:44:55Z","timestamp":1789523095561,"version":"build-2803163510"},"reference-count":10,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T00:00:00Z","timestamp":1700092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Trofinetide is the first drug approved by the FDA to treat Rett Syndrome in children aged 2\u00a0years or above. The drug significantly improved Rett syndrome behavioral scores Rett syndrome behavioral questionnaire in clinical studies. Although further research is needed to assess potential adverse events, Trofinetide\u2019s notable efficacy signifies a significant advancement in Rett syndrome treatment, offering a new therapeutic avenue with the potential to ameliorate the condition.<\/jats:p>","DOI":"10.3389\/fphar.2023.1284035","type":"journal-article","created":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T17:36:35Z","timestamp":1700156195000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Trofinetide\u2014a new chapter in rett syndrome\u2019s treatment"],"prefix":"10.3389","volume":"14","author":[{"given":"Muhammad","family":"Furqan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,16]]},"reference":[{"key":"B1","unstructured":"Acadia Pharmaceuticals announces U.S. FDA approval of DAYBUETM (trofinetide) for the treatment of Rett syndrome in adult and pediatric patients two years of age and older2023"},{"key":"B2","unstructured":"A randomized, double-blind, placebo-controlled, parallel-group study of trofinetide for the treatment of Girls and women with Rett syndrome clinicaltrials.gov2022"},{"key":"B3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jns.2008.12.003","article-title":"NNZ-2566: a Gly\u2013Pro\u2013Glu analogue with neuroprotective efficacy in a rat model of acute focal stroke","volume":"278","author":"Bickerdike","year":"2009","journal-title":"J. Neurological Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.12703\/r\/10-59","article-title":"Rett syndrome: think outside the (skull) box","volume":"10","author":"Borloz","year":"2021","journal-title":"Fac. Rev."},{"key":"B5","volume-title":"Rett syndrome","author":"Chahil","year":"2023"},{"key":"B6","unstructured":"FDA approves first treatment for Rett Syndrome2023"},{"key":"B7","doi-asserted-by":"publisher","first-page":"5114","DOI":"10.3390\/jcm12155114","article-title":"Trofinetide for Rett syndrome: highlights on the development and related inventions of the first USFDA-approved treatment for rare pediatric unmet medical need","volume":"12","author":"Hudu","year":"2023","journal-title":"J. Clin. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1038\/s41591-023-02398-1","article-title":"Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study","volume":"29","author":"Neul","year":"2023","journal-title":"Nat. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"106704","DOI":"10.1016\/j.cct.2022.106704","article-title":"Design and outcome measures of LAVENDER, a phase 3 study of trofinetide for Rett syndrome","volume":"114","author":"Neul","year":"2022","journal-title":"Contemp. Clin. Trials"},{"key":"B10","doi-asserted-by":"publisher","first-page":"12488","DOI":"10.3390\/ijms241512488","article-title":"Brain mitochondrial bioenergetics in genetic neurodevelopmental disorders: focus on Down, Rett and fragile X syndromes","volume":"24","author":"Valenti","year":"2023","journal-title":"Int. J. Mol. Sci."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1284035\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T17:36:38Z","timestamp":1700156198000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1284035\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,16]]},"references-count":10,"alternative-id":["10.3389\/fphar.2023.1284035"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1284035","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,16]]},"article-number":"1284035"}}